Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03 or MF59

NCT06560151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1380

Enrollment

FED

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: 3.75 µg H5N8 antigen plus full dose AS03A
BIOLOGICAL: 7.5 µg H5N8 antigen plus full dose AS03A
BIOLOGICAL: 15 µg H5N8 antigen plus full dose AS03A
BIOLOGICAL: 3.75 µg H5N8 antigen plus half dose AS03A
BIOLOGICAL: 7.5 µg H5N8 antigen plus half dose AS03A
BIOLOGICAL: 15 µg H5N8 antigen plus half dose AS03A
BIOLOGICAL: 3.75 µg H5N8 antigen plus MF59
BIOLOGICAL: 7.5 µg H5N8 antigen plus MF59
BIOLOGICAL: 15 µg H5N8 antigen plus MF59
BIOLOGICAL: 3.75 µg H5N1 antigen plus full dose AS03A
BIOLOGICAL: 7.5 µg H5N1 antigen plus full dose AS03A
BIOLOGICAL: 15 µg H5N1 antigen plus full dose AS03A
BIOLOGICAL: 3.75 µg H5N1 antigen plus MF59
BIOLOGICAL: 7.5 µg H5N1 antigen plus MF59
BIOLOGICAL: 15 µg H5N1 antigen plus MF59

Sponsor

Biomedical Advanced Research and Development Authority

Collaborators

[object Object]
[object Object]